SLV-324 for Metastatic Solid Tumors
This study is testing a new treatment called SLV-324 for people with metastatic solid tumors (cancers that have spread from where they started). SLV-324 is given as an intravenous (IV) infusion, meaning it goes directly into your vein. Researchers want to find out how safe SLV-324 is, how your body handles it, and if it can help treat these cancers. This treatment works by targeting specific pathways in the body (targeted therapy) and by boosting the body's immune system (immunotherapy). You might be able to join if you are 18 or older, have a solid tumor that has spread, and your cancer has gotten worse after previous treatments. The main goal is to find the highest dose of SLV-324 that can be given safely. The current status of this study is unclear.
- Study design
- This is a Phase 1 study designed to find the right dose of SLV-324. It plans to include about 70 participants.
- What's involved
- SLV-324 will be given intravenously in repeated cycles. Treatment will continue until your disease gets worse or you stop treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main safety and dose information will be collected throughout treatment, which could be up to about 18 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
SLV-324 Treatment of Metastatic Solid Tumors
At a glance
Conditions
NCT07108114
Where you'd take part
This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Fox Chase Cancer Center
Philadelphia, Pennsylvaniastudy coordinator listed
Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, Californiastudy coordinator listed
Recruiting
Mays Cancer Center; University of Texas Health San Antonio
Houston, Texasstudy coordinator listed
Recruiting
MD Anderson Cancer Center
Houston, Texasstudy coordinator listed
Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohiostudy coordinator listed
Recruiting
University of Washington / Fred Hutchinson Cancer Center
Seattle, Washingtonstudy coordinator listed
Recruiting
Washington University
St Louis, Missouristudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- MTD or RDRThrough the duration of treatment, up to approximately 18 months
Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-324